SCHEMBL21823785

SCHEMBL21823785

Clc1ccc2cc(-c3csc(-c4ccco4)n3)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.47
▸ MAPT P10636 8/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ HSD17B10 Q99714 4/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ KDM4C Q9H3R0 1/20 0.45
▸ ALOX15 P16050 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ PIK3R1 P27986 1/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823773 0.85 CYP19A1 (0.47) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL21823768 0.81 CYP19A1 (0.44) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL21823780 0.80 F2RL3 (0.45) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL21823779 0.80 F2RL3 (0.45) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL21824294 0.79 CYP19A1 (0.42) CYP19A1MAPTALDH1A1RAB9AKDM4E
SCHEMBL29546326 0.78 CYP19A1 (0.44) CYP19A1MAPTALDH1A1RAB9ALMNA
SCHEMBL7253210 0.77 CYP19A1 (0.72) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL29546209 0.76 F2RL3 (0.43) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL21823798 0.75 KDM4E (0.49) CYP19A1MAPTALDH1A1HSD17B10RAB9A
SCHEMBL29546491 0.75 RAB9A (0.46) CYP19A1MAPTALDH1A1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 — — EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 — — US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 — — EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP CYP19A1 2345/4885MAPT 1816/4885ALDH1A1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback